Search results
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
FierceBiotech· 3 days agoMuch of Moderna’s focus is on nabbing FDA approval for a respiratory syncytial virus vaccine, a...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 3 days agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...
Moderna Beats Quarterly Estimates as Cost-Cutting Pares Losses
Bloomberg· 3 days agoModerna Inc. reported a narrower first-quarter loss than Wall Street had expected, as the biotech...
Unveiling Moderna (MRNA) Q1 Outlook: Wall Street Estimates for Key Metrics
Zacks via Yahoo Finance· 6 days agoBeyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of...
Moderna quarterly sales beat expectations but plummet from previous year
Reuters via Yahoo Finance· 3 days agoModerna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was ...
Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlight
FierceBiotech· 3 days agoEarlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting stage left on a partnership worth up to $3 billion in biobucks. Back in 2021 ...
Why Earnings Season Could Be Great for Moderna (MRNA)
Zacks· 4 days agoFree Report) may be one such company. In fact, the Most Accurate Estimate for the current quarter is currently at a loss of $3.55 per share for MRNA, narrower than the broader Zacks Consensus ...
Smart Money Is Betting Big In MRNA Options - Moderna (NASDAQ:MRNA)
Benzinga· 4 days agoLoading... Loading... Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna . Looking at options history for Moderna MRNA ...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune· 2 days agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the market, its COVID-19 vaccine called Spikevax. The company’s first quarter ...
Moderna Inc (MRNA) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges with ...
GuruFocus.com via Yahoo Finance· 2 days agoRelease Date: May 02, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Moderna Inc (NASDAQ:MRNA) reported ...
